Physician profile
Melani Kellison
NPI 1588365613
$623.48
in general payments reported to CMS, 2019-2025
14 companies · $596 in 2025
The $596 reported for 2025 was more than what 78% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $27.28 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $623.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $623.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $217.08 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $76.54 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.43 | 2025 | Xifaxan |
| Tolmar, INC. | $43.95 | 2025 | Jatenzo |
| Astrazeneca Pharmaceuticals Lp | $40.13 | 2025 | Airsupra, Farxiga |
| Organon LLC | $27.28 | 2023 | Nexplanon |
| Pfizer INC. | $24.93 | 2025 | |
| Dexcom, INC. | $22.27 | 2025 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $22.16 | 2025 | Nexletol |
| Corium, LLC | $16.99 | 2025 | Azstarys |
| Amneal Pharmaceuticals LLC | $15.68 | 2025 | Unithroid |
| Amgen INC. | $15.38 | 2025 | Repatha, Otezla |
| Glaxosmithkline, LLC. | $14.90 | 2025 | Trelegy Ellipta |
| Antares Pharma, INC. | $14.76 | 2025 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melani Kellison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.